Memorial Sloan-Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.
Recent findings by Memorial Sloan-Kettering immunologists might one day pave the way for new strategies to control a range of diseases, including autoimmune disorders and cancer.
Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.
Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.
Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer.
At Memorial Sloan-Kettering, new technologies to study gene changes in cancer cells are accelerating the development and implementation of more-effective treatments.
In the lab of cancer biologist Scott Lowe, researchers are investigating the processes that naturally inhibit cancer development.
Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.
Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.
Memorial Sloan-Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.